Top

Published in:

01-01-2008 | Clinical Trial

Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?

Authors: Karin Leunen, Maria Drijkoningen, Patrick Neven, Maria-Rose Christiaens, Chantal Van Ongeval, Eric Legius, Frédéric Amant, Patrick Berteloot, Ignace Vergote

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Abstract

Objective To evaluate the indications, techniques and pathologic findings of prophylactic mastectomy (pME). Methods Retrospective study of patients with a strong family history of breast cancer (and ovarian cancer) or with proven BRCA mutation. Results Between January 1995 and December 2005, sixty seven patients underwent pME: 15% had a BRCA1 mutation, 31% had a BRCA2 mutation and 33% had a strong family history but without proven BRCA mutation and in 21% mutation analysis was not performed. Fifty eight percent had a personal history of breast cancer of which 84% previously underwent a unilateral mastectomy as part of their treatment. The median time to decision from previous treatment for breast carcinoma to pME was 46 months. Mean age at pME was 43 years. Pathologic examination of the pME specimens revealed invasive and/or in situ carcinoma in 19% (13/67). Atypical ductal/lobular hyperplasia (ADH/ALH) or flat epithelial atypia (FEA) were present in another 3%. Conclusion Twenty two percent of women at high risk for breast cancer presented at the time of pME with invasive carcinoma or intra-epithelial neoplasia undetected by imaging and clinical examination.

Van Eycken E, De Wever N (2006) Cancer incidence and Survival in Flanders, 2000–2001. Flemish Cancer Registry Network, VLK, Brussels

Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F (2006) Time trends of breast cancer survival in Europe in relation to incidence and mortality. Int J Cancer 119(10):2417–2222PubMedCrossRef

Mc Clain MR, Palomaki GE, Nathanson KL, Haddow JE (2005) Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 7:28–33CrossRef

Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al. (1994) A strong candidate for the breast and ovaria cancer susceptibility gene BRCA1. Science 266(5182):66–71PubMedCrossRef

Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–92PubMedCrossRef

Ford D, Easton DF, Stratton M et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: the Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689PubMedCrossRef

Struewing JP, Hartge P, Wacholder S et al. (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408PubMedCrossRef

Antoniou A, Pharoah PD, Narod S et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 of BRCA2 mutation detected in case Series unselected for family history: a combined analysis of 22 studies. Am H Hum Genet 72:1117–1130CrossRef

Hartmann LC, Schaid KJ, Woods JE et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77–84PubMedCrossRef

10.

Meijers-Heijboer H, van Geel B, van Putten WL et al. (2001) Breast cancer after prophylactic bilateral mastectomy in omen with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159–164PubMedCrossRef

11.

Rebbeck TR, Friebel T, Lynch HT (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 22:1055–1062PubMedCrossRef

12.

Calderon-Margalit R, Paltiel O (2004) Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J cancer 112:357–364PubMedCrossRef

13.

Rosen P, Groshen S, Kinne D, Hellman S (1989) Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20 year follow-up. Surgery 5:904–910

14.

Newman LA, Kuerer HM, Hung KK, Vlastos G, Ames FC, Ross MI, Singletary SE (2000) Prophylactic mastectomy. J Am Coll Surg 191(3):322–329PubMedCrossRef

15.

Scarff Rw, Torloni H (1968) Histological typing of breast tumors. International histological classification of tumors. World Health Org 2(2):13–20

16.

Elston CW, Ellis IO (1991) Pathologic prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef

17.

Scott CI, Iorgulescu DG, Thorne HJ, Henderson MA, Philips KA (2003) Clinical, pathologic and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. Clin Genet 64:111–121PubMedCrossRef

18.

Khurana KK, Loosmann A, Numann PJ, Khan SA (2000) Prophylactic mastectomy. Pathologic findings in high-risk patients. Arch Pathol Lab Med 124:378–381PubMed

19.

Hoogerbrugge N, Bul P, Bonenkamp JJ et al. (2006) Numerous high-risk epithelial lesions in familial breast cancer. Eur J Cancer

20.

Van de Groep P, Bouter A, van der Zanden R et al. (2006) Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pahtol 59:611–617CrossRef

21.

Honrado E, Osorio A, Palacios J, Benitez J (2006) Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 25:5837–5845PubMedCrossRef

22.

Sun CC, Lenoir G, Lynch H, Narod SA (1996) In-situ breast cancer and BRCA1[letter]. Lancet 348:1098

23.

Jacquemeir J, Eisinger F, Guinebretier JM, Stoppa-Lyonnet D, Sobol H (1996) Intraductal component and BRCA1-associated breast cancer [letter]. Lancet 348:1098CrossRef

24.

Adam C, Reynolds C, Soderberg CL et al. (2003) Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 97:1–11CrossRef

25.

Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J (2006) Prognostic significance of basal-like photype and Fascin expression in Node negative invasive breast carcinomas. Clin Cancer Res 12(5):1533–1539PubMedCrossRef

26.

Rodriguez-Pinilla SM, Sarrio D, Honrado E et al. (2006) Prognostic Significance of basal like phenotyp and fasin expresión in node-negative invasive breast carcinomas. Clin Caner Res 12(5):1533–1539CrossRef

27.

Honrado E, Benitez J, Palacios J (2006) Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit rev oncol hematol 59:27–39PubMedCrossRef

28.

Pierce LJ, Levin AM, Rebbeck TR et al. (2006) Ten-Year Multi-institutional results of breast conserving surgery and radiothearapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24:2437–2443PubMedCrossRef

29.

Turner BC, Harrold E, Matloff et al. (1999) BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 17:3017–3024PubMed

30.

Robson M, Svahn T, McCormick B, Borgen P, Hudis CA, Norton L, Offit K (2005) Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2. Cancer 103:44–51PubMedCrossRef

31.

Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of conservatively managed early onset breast cancer by BRCA1/2 status. Lancet 359:1471–1477PubMedCrossRef

32.

Rebbeck RT, Lynch HT, Neuhausen SL et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622PubMedCrossRef

33.

Kramer JL, Velaquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH (2005) Prophylactic oophorectomy reduces breast cancer penetrance during prospective long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 23(34):8629–8635PubMedCrossRef

34.

Kauff ND, Brogi E, Scheuer L et al. (2003) Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 97:1601–1608PubMedCrossRef

35.

CIS of the breast, Silverstein MJ, Baril C (2002) Cancer of the breast. Donegan & Spratt. 5th edition

36.

Margenthaler JA, Duke D, Monsees BS, Barton P, Clark C, Dietz JR (2006) Correlation between core biopsy and excional biopsy in breast highr-risk lesions. Am J Surg 192:534–537PubMedCrossRef

37.

Kuhl KC, Schrading S, Leutner CC et al. (2006) Mammography, breast ultrasound and magnetic resonance imaging for surveillance of women at high famila risk for breast cancer. J Clin Oncol 23:8469–8476CrossRef

38.

Kauff ND, Satagopan JM, Robson ME et al. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615PubMedCrossRef

39.

Olson JE, Sellers TA, Iturria SJ, Hartmann LC. (2004) Bilateral oophorectomy and breast cancer risk reduction among women with a family history. Cancer detect prev 28:357–360PubMedCrossRef

40.

Rebbeck TR (2002) Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer 38(S6):S15–S17PubMedCrossRef

41.

Eisen A, Lubinski J, Klijn J et al. (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23(30):749–846CrossRef

Title: Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?
Authors: Karin Leunen
Maria Drijkoningen
Patrick Neven
Maria-Rose Christiaens
Chantal Van Ongeval
Eric Legius
Frédéric Amant
Patrick Berteloot
Ignace Vergote
Publication date: 01-01-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9525-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Activation of protein kinase A (PKA) signaling mitigates the antiproliferative and antiinvasive effects of α-difluoromethylornithine in breast cancer cells

BARD1 and breast cancer in Poland

Screening for ATM sequence alterations in African-American women diagnosed with breast cancer

Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer

Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation

Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer